Prevention and management of tuberculosis in transplant recipients: From guidelines to clinical practice

Transplantation

Volumn 100, Issue 9, 2016, Pages 1840-1852

  Muñoz, Laura ^a,b   Santin, Miguel ^a,b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; ISONIAZID; ISONIAZID PLUS RIFAMPICIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; IMMUNOSUPPRESSIVE AGENT; TUBERCULOSTATIC AGENT;

ALGORITHM; CLINICAL PRACTICE; CONSENSUS; EVIDENCE BASED MEDICINE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RISK; KIDNEY DONOR; MEDICAL SOCIETY; MICROBIOLOGICAL EXAMINATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; ORGAN TRANSPLANTATION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROTOCOL COMPLIANCE; REVIEW; RISK ASSESSMENT; TUBERCULOSIS; TUBERCULOSIS CONTROL; ADVERSE EFFECTS; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MICROBIOLOGY; OPPORTUNISTIC INFECTIONS; RISK FACTOR; STANDARDS; TRANSMISSION; TREATMENT OUTCOME;

ANTITUBERCULAR AGENTS; EVIDENCE-BASED MEDICINE; GRAFT SURVIVAL; GUIDELINE ADHERENCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; OPPORTUNISTIC INFECTIONS; ORGAN TRANSPLANTATION; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84974849184     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001224     Document Type: Review

References (95)

1. WHO. Guidelines on the Management of Latent Tuberculosis Infection. Geneva, Switzerland: World Health Organization; 2014.
2. WHO. Global Tuberculosis Report 2015. Geneva, Switzerland: World Health Organization; 2015.
3. Comstock G, Livesay V, Woolpert S. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol. 1974;99:131-138.
4. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep. 2000;49:1-51.
5. Singh N, Paterson DL. Mycobacterium tuberculosis infection in solidorgan transplant recipients: impact and implications for management. Clin Infect Dis. 1998;27:1266-1277.
6. Aguado JM, Herrero JA, Gavaldá J, et al. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA. Transplantation. 1997;63:1278-1286.
7. Bucher JN, Schoenberg MB, Freytag I, et al. Donor-derived tuberculosis after solid organ transplantation in two patients and a staff member. Infection. 2015.
8. Torre-Cisneros J, Doblas A, Aguado JM, et al. Tuberculosis after solidorgan transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis. 2009;48:1657-1665.
9. Naqvi A, Rizvi A, Hussain Z, et al. Developing world perspective of posttransplant tuberculosis: morbidity, mortality, and cost implications. Transplant Proc. 2001;33:1787-1788.
10. Sharma AK, Tolani SL, Rathi GL, et al. Tuberculosis after renal transplantation. Transplant Proc. 2000;32:1959.
11. Zhang X, Lv Y, Xue W, et al. Mycobacterium tuberculosis infection in solid organ transplant recipients: experience from a single center in China. Transplant Proc. 2008;40:1382-1385.
12. Chou NK, Wang JL, Chi NH, et al. Tuberculosis after heart transplantation: Twenty years of experience in a single center in Taiwan. Transplant Proc. 2008;40:2631-2633.
13. Jung JY, Joo DJ, Lee CH, et al. Pre-transplant risk factors for tuberculosis after kidney transplant in an intermediate burden area. Int J Tuberc Lung Dis. 2012;16:248-254.
14. Dromer C, Nashef SA, Velly JF, et al. Tuberculosis in transplanted lungs. J Heart Lung Transplant. 1993;12:924-927.
15. de la Cámara, R, Martino R, Granados E, et al. Tuberculosis after hematopoietic stem cell transplantation: incidence, clinical characteristics and outcome. Spanish Group on Infectious Complications in Hematopoietic Transplantation. Bone Marrow Transplant. 2000;62:291-298.
16. Fan WC, Liu CJ, Hong YC, et al. Long-term risk of tuberculosis in haematopoietic stem cell transplant recipients: A 10-year nationwide study. Int J Tuberc Lung Dis. 2015;19:58-64.
17. Lee YM, Lee SO, Choi SH, et al. A prospective longitudinal study evaluating the usefulness of the interferon-gamma releasing assay for predicting active tuberculosis in allogeneic hematopoietic stem cell transplant recipients. J Infect. 2014;69:165-173.
18. Stagg HR, Zenner D, Harris RJ, et al. Treatment of latent tuberculosis infection: A network meta- Analysis. Ann Intern Med. 2014;161:419-428.
19. Falk A, Fuchs GF. Prophylaxis with isoniazid in inactive tuberculosis. A Veterans Administration Cooperative Study XII. Chest. 1978;73:44-48.
20. Akolo C, Adetifa I, Shepperd S, et al. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010;1: CD000171.
21. World Health Organization. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ. 1982;60:555-564.
22. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treatedwith tumor necrosis factor antagonists. Arthritis Rheum. 2005;52:1766-1772.
23. Currie AC, Knight SR, Morris PJ. Tuberculosis in renal transplant recipients: The evidence for prophylaxis. Transplantation. 2010;90:695-704.
24. Holty JE, Gould MK, Meinke L, et al. Tuberculosis in liver transplant recipients: A systematic review and meta- Analysis of individual patient data. Liver Transpl. 2009;15:894-906.
25. Bumbacea D, Arend SM, Eyuboglu F, et al. The risk of tuberculosis in transplant candidates and recipients: A TBNET consensus statement. Eur Respir J. 2012;40:990-1013.
26. Meije Y, Piersimoni C, Torre-Cisneros J, et al. ESCMID Study Group of Infection in Compromised Hosts. Mycobacterial infections in solid organ transplant recipients. Clin Microbiol Infect. 2014;20:89-101.
27. Aguado JM, Torre-Cisneros J, Fortún J, et al. Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis. 2009;48:1276-1284.
28. Subramanian AK, Morris MI, AST Infectious Diseases Community of Practice. Mycobacterium tuberculosis infections in solid organ transplantation. Am J Transplant. 2013;13:68-76.
29. Martin P, DiMartini A, Feng S, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014;59:1144-1165.
30. Milburn H, Ashman N, Davies P, et al. Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. Thorax. 2010;65: 557-570.
31. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: A global perspective. Preface. Bone Marrow Transplant. 2009;44:453-455.
32. Muñoz L, Casas S, Juanola X, et al. Prevention of anti-tumor necrosis factor- Associated tuberculosis: A 10-year longitudinal cohort study. Clin Infect Dis. 2015;60:349-356.
33. Santin M, Domínguez J. Diagnosis of tuberculosis infection using interferon-γ-based assays. Enferm Infecc Microbiol Clin. 2014;29:26-33.
34. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: An update. Ann Intern Med. 2008;149:177-184.
35. Diel R, Loddenkemper R, Nienhaus A. Predictive value of interferon-γ release assays and tuberculin skin testing for progression from latent TB infection to disease state: A meta- Analysis. Chest. 2012;142:63-75.
36. Kim SH, Lee SO, Park JB, et al. A prospective longitudinal study evaluating the usefulness of a T-cell-based assay for latent tuberculosis infection in kidney transplant recipients. Am J Transplant. 2011;11:1927-1935.
37. Lange B, Vavra M, Kern WV, et al. Development of tuberculosis in immunocompromised patients with a positive tuberculosis-specific IGRA. Int J Tuberc Lung Dis. 2012;16:492-495.
38. Theodoropoulos N, Lanternier F, Rassiwala J, et al. Use of the QuantiFERON-TB Gold interferon-gamma release assay for screening transplant candidates: A single-center retrospective study. Transpl Infect Dis. 2012;14:1-8.
39. Jeong JC, Koo TY, Jeon HJ, et al. Utility of QuantiFERON-TB assay for prediction of tuberculosis development in kidney transplant patients in an intermediate-tuberculosis-burden country: lack of evidence for enhanced prediction for short-term tuberculosis development. Transplant Proc. 2014;46:583-587.
40. Muñoz L, Gomila A, Casas S, et al. Immunodiagnostic tests' predictive values for progression to tuberculosis in transplant recipients. Transplant Direct. 2015:1.
41. Kim SH, Lee SO, Park IA, et al. Isoniazid treatment to prevent TB in kidney and pancreas transplant recipients based on an interferon-γ-releasing assay: An exploratory randomized controlled trial. J Antimicrob Chemother. 2015;70:1567-1572.
42. Moon SM, Park IA, Kim SM, et al. Living donor and recipient screening for latent tuberculosis infection by tuberculin skin test and interferon-gamma releasing assay in a country with an intermediate burden of tuberculosis. J Infect Chemother. 2013;19:1009-1013.
43. Diel R, Loddenkemper R, Nienhaus A. Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB a metaanalysis. Chest. 2010;137:952-968.
44. Sester M, van Leth, F, Bruchfeld J, et al. Risk assessment of tuberculosis in immunocompromised patients. A TBNET study. Am J Respir Crit Care Med. 2014;190:1168-1176.
45. Sester U, Wilkens H, van Bentum, K, et al. Impaired detection of Mycobacterium tuberculosis immunity in patients using high levels of immunosuppressive drugs. Eur Respir J. 2009;34:702-710.
46. Kim S, Song K, Choi S, et al. Diagnostic usefulness of a T-cell-based assay for extrapulmonary tuberculosis in immunocompromised patients. Am J Med. 2009;122:189-195.
47. Redelman-Sidi G, Sepkowitz KA. IFN-γ release assays in the diagnosis of latent tuberculosis infection among immunocompromised adults. Am J Respir Crit Care Med. 2013;188:422-431.
48. Scholman T, Straub M, Sotgiu G, et al. Superior sensitivity of ex vivo IFN-γ release assays as compared to skin testing in immunocompromised patients. Am J Transplant. 2015;15:2616-2624.
49. Lyu J, Lee SG, Hwang S, et al. Chest computed tomography ismore likely to show latent tuberculosis foci than simple chest radiography in liver transplant candidates. Liver Transplant. 2011;17:963-968.
50. Agoglia L, Balbi E, Halpern M, et al. Tuberculosis in liver transplant recipients: prophylaxis in an endemic area. Transplant Proc. 2011;43:199-202.
51. Jafri SM, Singal AG, Kaul D, et al. Detection andmanagement of latent tuberculosis in liver transplant patients. Liver Transpl. 2011;17:306-314.
52. Stucchi RS, Boin IF, Angerami RN, et al. Is isoniazid safe for liver transplant candidates with latent tuberculosis? Transplant Proc. 2012;44:2406-2410.
53. Fábrega E, Sampedro B, Cabezas J, et al. Chemoprophylaxis with isoniazid in liver transplant recipients. Liver Transpl. 2012;18:1110-1117.
54. Spence R, Dafoe D, Rabin G, et al. Mycobacterial infections in renal allograft recipients. Arch Surg. 1983;118:356-359.
55. Higgins R, Cahn A, Porter D, et al. Mycobacterial infections after renal transplantation. Q J Med. 1991;78:145-153.
56. Yildiz A, Sever MS, Türkmen A, et al. Tuberculosis after renal transplantation: experience of one Turkish centre. Nephrol Dial Transplant. 1998;13: 1872-1875.
57. Sayiner A, Turhan E, Duman S, et al. Tuberculosis in renal transplant recipients. Transplantation. 1999;68:1268-1271.
58. Apaydin S, Altiparmak M, Serdengeçti K, et al. Mycobacterium tuberculosis infections after renal transplantation. Scand J Infect Dis. 2000;32: 501-505.
59. Matuck TA, Brasil P, Alvarenga M de F, et al. Tuberculosis in renal transplants in Rio de Janeiro. Transplant Proc. 2004;36:905-906.
60. John G, Thomas P, Thomas M, et al. A double-blind randomized controlled trial of primary isoniazid prophylaxis in dialysis and transplant patients. Transplantation. 1994;57:1683-1684.
61. Agarwal SK, Gupta S, Dash SC, et al. Prospective randomised trial of isoniazid prophylaxis in renal transplant recipient. Int Urol Nephrol. 2004;36: 425-431.
62. Vikrant S, Agarwal S, Gupta S, et al. Prospective randomized control trial of isoniazid chemoprophylaxis during renal replacement therapy. Transpl Infect Dis. 2005;7:99-108.
63. Naqvi R, Naqvi A, Akhtar S, et al. Use of isoniazid chemoprophylaxis in renal transplant recipients. Nephrol Dial Transplant. 2010;25:634-637.
64. Offermann G, Keller F. Low cyclosporin A blood levels and acute graft rejection in a renal transplant recipient during rifampin treatment. Am J Nephrol. 1985;5:385-387.
65. Paterson DL, Singh N. Interactions between tacrolimus and antimicrobial agents. Clin Infect Dis. 1997;25:1430-1440.
66. Kovarik JM, Hartmann S, Figueiredo J, et al. Effect of rifampin on apparent clearance of everolimus. Ann Pharmacother. 2002;36:981-985.
67. Torre-Cisneros J, San Juan R, Rosso-Fernández CM, et al. Tuberculosis prophylaxis with levofloxacin in liver transplant patients is associated with a high incidence of tenosynovitis: safety analysis of a multicenter randomized trial. Clin Infect Dis. 2015;60:1642-1649.
68. Stennis NL, Burzynski JN, Herbert C, et al. Treatment for tuberculosis infection with 3 months of isoniazid and rifapentine in New York City Health Department Clinics. Clin Infect Dis. 2015;62:53-59.
69. Sidhu A, Verma G, Humar A, et al. Outcome of latent tuberculosis infection in solid organ transplant recipients over a 10-year period. Transplantation. 2014;98:671-675.
70. Jahng AW, Tran T, Bui L, et al. Safety of treatment of latent tuberculosis infection in compensated cirrhotic patients during transplant candidacy period. Transplantation. 2007;83:1557-1562.
71. Bliven-Sizemore EE, Sterling TR, Shang N, et al. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI. Int J Tuberc Lung Dis. 2015;19:1039-1044.
72. Sterling T, Villarino M, Borisov A, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365: 2155-2166.
73. Martinson NA, Barnes GL, Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med. 2011;365:11-20.
74. de Castilla DL, Rakita RM, Spitters CE, et al. Short-course isoniazid plus rifapentine directly observed therapy for latent tuberculosis in solid-organ transplant candidates. Transplantation. 2014;97:206-211.
75. Heifets LB, Lindholm-Levy PJ, Iseman MD. Rifabutine: minimal inhibitory and bactericidal concentrations for Mycobacterium tuberculosis. Am Rev Respir Dis. 1988;137:719-721.
76. Ji B, Truffot-Pernot C, Lacroix C, et al. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis. 1993;148:1541-1546.
77. BurmanWJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet. 2001;40:327-341.
78. Williamson B, Dooley KE, Zhang Y, et al. Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine. Antimicrob Agents Chemother. 2013;57:6366-6369.
79. Horne DJ, NaritaM, Spitters CL, et al. Challenging issues in tuberculosis in solid organ transplantation. Clin Infect Dis. 2013;57:1473-1482.
80. Hickey MD, Quan DJ, Chin-Hong PV, et al. Use of rifabutin for the treatment of a latent tuberculosis infection in a patient after solid organ transplantation. Liver Transpl. 2013;19:457-461.
81. Tien V, Robilotti E, Callister D, et al. Tolerability of fluoroquinolones in management of latent tuberculosis in liver transplant candidates. Clin Infect Dis. 2015;61:1631-1632.
82. Anibarro L, Casas S, Paz-Esquete J, et al. Treatment completion in latent tuberculosis infection at specialist tuberculosis units in Spain. Int J Tuberc Lung Dis. 2010;14:701-707.
83. Morris MI, Daly JS, Blumberg E, et al. Diagnosis and management of tuberculosis in transplant donors: A donor-derived infections consensus conference report. Am J Transplant. 2012;12:2288-2300.
84. Schmidt T, Schub D, Wolf M, et al. Comparative analysis of assays for detection of cell-mediated immunity toward cytomegalovirus and M. tuberculosis in samples from deceased organ donors. Am J Transplant. 2014;14:2159-2167.
85. Mortensen E, Hellinger W, Keller C, et al. Three cases of donor-derived pulmonary tuberculosis in lung transplant recipients and review of 12 previously reported cases: opportunities for early diagnosis and prevention. Transpl Infect Dis. 2014;16:67-75.
86. Naqvi R, Akhtar S, Noor H, et al. Efficacy of isoniazid prophylaxis in renal allograft recipients. Transplant Proc. 2006;38:2057-2058.
87. Chenhsu RY, Loong CC, Chou MH, et al. Renal allograft dysfunction associated with rifampin-tacrolimus interaction. Ann Pharmacother. 2000;34:27-31.
88. Davies G, Cerri S, Richeldi L. Rifabutin for treating pulmonary tuberculosis. Cochrane Database Syst Rev. 2007;17:CD005159.
89. Rawson TM, Brima N, Almajid F, et al. Outcomes from treating tuberculosis with rifampicin or rifabutin in HIV-infected persons also receiving antiretroviral therapy. J Acquir Immune Defic Syndr. 2014;68: e84-e87.
90. Lee J, Yew WW, Wong CF, et al. Multidrug-resistant tuberculosis in a lung transplant recipient. J Heart Lung Transplant. 2003;22: 1168-1173.
91. Muñoz P, Palomo J, Muñoz R, et al. Tuberculosis in heart transplant recipients. Clin Infect Dis. 1995;21:398-402.
92. Tabarsi P, Farshidpour M, Marjani M, et al. Mycobacterial infection and the impact of rifabutin treatment in organ transplant recipients: A single-center study. Saudi J Kidney Dis Transpl. 2015;26:6-11.
93. Jindani A, Harrison TS, Nunn AJ, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014;371: 1599-1608.
94. Maynard-Smith L, Fernando B, Hopkins S, et al. Managing latent tuberculosis in UK renal transplant units: how does practice compare with published guidance? Clin Med. 2014;14:26-29.
95. Cordonnier C, Martino R, Trabasso P, et al. Mycobacterial infection: A difficult and late diagnosis in stem cell transplant recipients. Clin Infect Dis. 2004;38:1229-1236.